One company has been in business for 130 years. The other got its start as a stand-alone entity in 2013. But both Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) have rewarded shareholders with solid gains and nice dividends in the past few years. Which is the better pick for investors now?